Publications by authors named "Louis F Fabre"
Article Synopsis
- Sexual dysfunction is a common issue in men with major depressive disorder (MDD), often exacerbated by traditional antidepressants like SSRIs, but gepirone-ER shows promise in improving sexual function without these adverse effects.
- In an 8-week double-blind study, gepirone-ER was found to significantly enhance sexual function compared to placebo and fluoxetine, especially in areas like orgasm quality.
- The study concluded that gepirone-ER effectively improved sexual function in depressed men, even in those who did not respond to conventional antidepressants.
Article Synopsis
- A study assessed the impact of depression on sexual function in 1,184 depressed women over 8 weeks, comparing the effects of gepirone-extended release to a placebo for treating major and atypical depressive disorders.
- The research aimed to explore how depression influences the prevalence of sexual dysfunction diagnoses based on DSM-IV criteria and to measure changes in sexual function using the Derogatis Inventory of Sexual Function (DISF) scale.
- Results indicated that while specific sexual dysfunction diagnoses in depressed women were within normal ranges, their overall sexual function scores were significantly lower than those of nondepressed populations, with higher depression severity linked to greater sexual dysfunction.
Article Synopsis
- Gepirone-extended release (ER) effectively treats hypoactive sexual desire disorder (HSDD) in women, showing improvement in sexual desire measured by the DeRogatis Inventory of Sexual Function (DISF).
- The study aimed to assess the impact of gepirone-ER on sexual desire independent of its antidepressant and anxiolytic effects, using both the Hamilton Depression Rating Scale (HAMD-25) and DISF for analysis.
- Results indicated that gepirone-ER improves sexual desire in both short and long term, regardless of patients' response to its antidepressant or anxiolytic effects.
Article Synopsis
- The FDA has not approved any treatment for hypoactive sexual desire disorder (HSDD), and recent attempts to approve testosterone products were halted due to safety concerns; meanwhile, flibanserin was also recently denied approval.
- The study aimed to evaluate the effects of gepirone-ER on HSDD in women suffering from major depressive disorder, comparing it to other antidepressants and a placebo.
- Out of 875 women studied, 63% of those treated with gepirone-ER no longer met HSDD criteria after 8 weeks, significantly outperforming the placebo group (40%), with noticeable improvements starting as early as 2 weeks into treatment.
Curr Ther Res Clin Exp
September 2003
Article Synopsis
- - Gepirone is a new antidepressant that targets 5-HT1A receptors, showing effectiveness and safety in treating depression, with previous studies indicating that food intake affects its bioavailability.
- - The article summarizes two studies on the pharmacokinetics of gepirone extended release (ER), focusing on how food intake and timing influence its absorption in healthy male subjects.
- - Results demonstrated a significant increase in peak plasma concentration of gepirone ER when taken after a meal compared to fasting, indicating that food has a considerable impact on its effectiveness.
